Abstract:Background: Repeat–induced epigenetic changes are observed in many repeat expansion disorders (REDs). These changes result in transcriptional deficits and/or silencing of the associated gene. MSH2, a mismatch repair protein that is required for repeat expansion in the REDs, has been implicated in the maintenance of DNA methylation seen in the region surrounding expanded CTG repeats at the DMPK locus in myotonic dystrophy type 1 (DM1). Here, we investigated the role of MSH2 in aberrant DNA methylation in two additional REDs, fragile X syndrome (FXS) that is caused by a CGG repeat expansion in the 5′ untranslated region (UTR) of the fragile X messenger ribonucleoprotein 1 ( ) gene, and Friedreich′s ataxia (FRDA) that is caused by GAA repeat expansion in intron 1 of the ( ) gene. Results: In contrast to what is seen at the locus in DM1, loss of MSH2 did not decrease DNA methylation at the promoter in FXS embryonic stem cells (ESCs) or increase transcription. This difference was not due to the differences in the CpG density of the two loci as a decrease in DNA methylation was also not observed in a less CpG dense region upstream of the expanded GAA repeats in the gene in MSH2 null induced pluripotent stem cells (iPSCs) derived from FRDA patient fibroblasts. Surprisingly given previous reports, we found that reactivation was associated with a high frequency of MSH2–independent repeat contractions that resulted a permanent loss of DNA methylation. Conclusions: Our results suggest that there are mechanistic differences in the way that DNA methylation is maintained in the vicinity of expanded repeats among different REDs even though they share a similar mechanism of repeat expansion. The high frequency of transcription-induced MSH2-independent contractions we have observed may contribute to the mosaicism that is frequently seen in carriers of alleles with expanded CGG-repeat tracts. Given the recent interest in the therapeutic use of transcription-driven repeat contractions, our data may have interesting mechanistic, prognostic, and therapeutic implications.

Reactivation Of Fmr1 By Crispr/Cas9-Mediated Deletion Of The Expanded Cgg-Repeat Of The Fragile X Chromosome

Targeted Reactivation of FMR1 Transcription in Fragile X Syndrome Embryonic Stem Cells

Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene.

High Throughput Small Molecule Screen for Reactivation of FMR1 in Fragile X Syndrome Human Neural Cells

Small Molecules Targeting H3K9 Methylation Prevent Silencing of Reactivated FMR1 Alleles in Fragile X Syndrome Patient Derived Cells

Epigenetic insights into Fragile X Syndrome

Cell-type-specific profiling of human cellular models of fragile X syndrome reveal PI3K-dependent defects in translation and neurogenesis

Integrated Transcriptome Analysis of Human Ips Cells Derived from a Fragile X Syndrome Patient During Neuronal Differentiation

EZH2 inhibition reactivates epigenetically silenced FMR1 and normalizes molecular and electrophysiological abnormalities in fragile X syndrome neurons

New perspectives on the biology of fragile X syndrome.

Increased Coupling Of Caveolin-1 And Estrogen Receptor Alpha Contributes To The Fragile X Syndrome

Maturation Delay of Human GABAergic Neurogenesis in Fragile X Syndrome Pluripotent Stem Cells

Potential Pharmacological Treatment of Fragile X Syndrome During Adulthood

Deletion of the KH1 Domain of Fmr1 Leads to Transcriptional Alterations and Attentional Deficits in Rats

Identification of Fragile X Syndrome Specific Molecular Markers in Human Fibroblasts: A Useful Model to Test the Efficacy of Therapeutic Drugs

FMRP(1–297)-tat restores ion channel and synaptic function in a model of Fragile X syndrome

Gene Therapy Using Human FMRP Isoforms Driven by the Human FMR1 Promoter Rescues Fragile X Syndrome Mouse Deficits.

The fragile X locus is prone to spontaneous DNA damage that is preferentially repaired by nonhomologous end-joining to preserve genome integrity

MSH2 is not required for either maintenance of DNA methylation or repeat contraction at the FMR1 locus in fragile X syndrome

Alleviating GAA Repeat Induced Transcriptional Silencing of the Friedreich's Ataxia Gene During Somatic Cell Reprogramming

An iPSC model of fragile X syndrome reflects clinical phenotypes and reveals m6A-mediated epi-transcriptomic dysregulation underlying synaptic dysfunction